ABSTRACT Objective To research the possible protection mechanism of total glucosides of paeony（TGP） in patients with chronic kidney disease（CKD）. Methods Totally 56 patients with stage Ⅱ to Ⅲ CKD were randomized into the treatment group and control group

with 28 in each. Both groups were given basic treatment. The control group was added with 50mg dipyridamole tablets three times daily

while the treatment group was added with 0. 6 g TGP capsules three times daily. The treatment lasted for 8 weeks. The changes of 24 h urine total protein（24h-UTP）

serum albumin（Alb）

serum creatinine（Scr）

creatinine clearance（Ccr）

interleukin-6（IL-6） and transforming growth factor-β1（ TGF-β1） were observed before and after treatment. Results The level of IL-6 was significantly decreased in the control group after treatment（ P < 0. 05）. The Scr

Ccr

IL-6 and TGF-β1 were significantly improved in the treatment group after treatment（ P < 0. 01）. Comparing with the control group

Scr

Ccr

IL-6 and TGF-β1 were significantly improved in the treatment group after treatment（ P < 0. 05 or P < 0. 01）. The Spearman correlation analysis showed that TGF-β1 was positively correlated with IL-6（ r = 0. 858

P < 0. 01）. Conclusion TGP can delay the process of CKD possibly by down-regulating the level of IL-6 and inhibiting the expression of TGF-β1.